Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19

Ali S. Omrani, Sameer A. Pathan, Sarah A. Thomas, Tim R.E. Harris, Peter Coyle, Caroline E. Thomas, Isma Qureshi, Zain A. Bhutta, Naema Al Mawlawi, Reham A. Al Kahlout,

EClinicalMedicine · 2020 · 73 citations · 19 references

DOIFull text

Open access

Concepts

Abstract

BACKGROUND: Hydroxychloroquine (HC) ± azithromycin (AZ) is widely used for Covid-19. The Qatar Prospective RCT of Expediting Coronavirus Tapering (Q-PROTECT) aimed to assess virologic cure rates of HC±AZ in cases of low-acuity Covid-19. METHODS: testing. (ClinicalTrials.gov NCT04349592, trial status closed to new participants.). FINDINGS: = 0·072) between study group and viral cure: HC+AZ 30/149 (20·1%,), HC 42/146 (28·8%), placebo 45/143 (31·5%). There were no serious adverse events. INTERPRETATION: HC±AZ does not facilitate virologic cure in patients with mild or asymptomatic Covid-19. FUNDING: The study was supported by internal institutional funds of the Hamad Medical Corporation (government health service of the State of Qatar).

References

19